Compounds and methods of use thereof for assaying lysophospholipase D activity
Fluorogenic lysophosphatidic acid derivatives which can be used as substrates in a continuous, fluorogenic assay that can be performed in microtiter plates. The assays permit measuring LysoPLD activity levels in normal events such as pregnancy or disease states such as cancer. In addition, the present invention can be adopted to high throughout screening(HTS) for identification of potential inhibitors of lysoPLD activity.
1. A method for assaying the lysophospholipase D (LysoPLD) activity of autotoxin (ATX) comprising the steps of:
a) obtaining a solution having ATX present;
b) adding a LysoPLD substrate comprising a lysophospholipid derivative labeled with a fluorescent group and a quencher group to said solution containing ATX; and
c) determining if LysoPLD activity is present in said solution by measuring the change in the fluorescent signal in said solution that is generated by the cleavage of said lysophospholipid derivative represented by the formula:
wherein A represents O or S; B represents H, Na + , K + , Li + or an alkyl group having 1-20 carbon atoms; E represents O, CH 2 , CHF or CF 2 ; G represents H, OH, F, O-acyl or O-alkyl having 1-20 carbon atoms; K 1 and K 2 each represent H, F, alkyl having 1 to 20 carbon atoms, OH or CO 2 H;W is C(O), NH(CH 2 CH 2 O) q C(O) or (NHC(O)(CH 2 ) n ) p C(O), wherein q is an integer from 1 to 33; n is an integer from 1 to 12; and p is an integer from 1 to 20; X represents NH; Y represents O, S or NH; Z is C(O)(CH 2 ) n (C)NH, (CH 2 CH 2 O) q C(O)NH or (CH 2 ) n NH wherein n is an integer from 1 to 33; and R 1 and R 2 are a fluorescent group or a quencher, respectively.
2. The method according to claim 1 , wherein said assay is a plate-based assay employing a multi- well microtiter plate.
3. The method according to claim 1 , wherein the assay is a fluorescence resonance energy transfer(FRET) assay or time-resolved fluorescence resonance energy transfer(TR-FRET) assay.
4. The method according to claim 1 , wherein said lysophospholipid derivative is a member selected from the group consisting of:
5. A method of screening for breast cancer, lung cancer, ovarian cancer, prostate cancer, colon cancer, renal cell carcinomas, and Hodgkin's lymphoma comprising determining the level of LysoPLD activity of ATX in bodily tissue, blood, or serum samples using the method of claim 1 .
6. A method for determining the status of breast cancer, lung cancer, ovarian cancer, prostate cancer, colon cancer, renal cell carcinomas, and Hodgkin's lymphoma comprising monitoring levels of Lyso PLD activity of ATX in bodily tissue, blood, or serum samples using the method of claim 1 .